An experimental immune-based therapy more than doubled median survival of patients diagnosed with the most aggressive malignant brain tumor, Cedars-Sinai Medical Center researchers reported in Cancer Immunology, Immunotherapy, published online. Median survival in a Phase I clinical trial at Cedars-Sinai's Johnnie L. Cochran, Jr. Brain Tumor Center was 38.4 months, significantly longer than the typical 14.6-month survival of patients with newly diagnosed glioblastoma receiving standard therapy alone, which includes radiation and chemotherapy...
Fonte: healthnews.com
Indique esta NotÃcia
Compartilhar
A PHP Error was encountered
Severity: User Warning
Message: Smarty error: unable to read resource: "indiquemat_healthnews.tpl"
Filename: libs/Smarty.class.php
Line Number: 1095
